[LGD1069: an antagonist to the X retinoid receptor].
Lansiaux
A
A
Laboratoire de pharmacologie antitumorale, Centre Oscar-Lambret et unité 524 Inserm, IRCL, place de Verdun, 59045 Lille Cedex, France.
Formstecher
P
P
Bailly
C
C
D000818:Animals; D016588:Anticarcinogenic Agents / Q000737:chemistry / Q000494:pharmacology*; D000077610:Bexarotene; D002478:Cells, Cultured; D002986:Clinical Trials as Topic; D019281:Dimerization; D003875:Drug Eruptions / Q000209:etiology; D004341:Drug Evaluation; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D016399:Lymphoma, T-Cell / Q000188:drug therapy; D051379:Mice; D051381:Rats; D018168:Receptors, Retinoic Acid / Q000037:antagonists & inhibitors*; D047488:Retinoid X Receptors; D012878:Skin Neoplasms / Q000188:drug therapy; D013329:Structure-Activity Relationship; D013764:Tetrahydronaphthalenes / Q000737:chemistry / Q000494:pharmacology*; D014157:Transcription Factors / Q000037:antagonists & inhibitors*; D015533:Transcriptional Activation
D016588:Anticarcinogenic Agents; D018168:Receptors, Retinoic Acid; D047488:Retinoid X Receptors; D013764:Tetrahydronaphthalenes; D014157:Transcription Factors; D000077610:Bexarotene